Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

NCT03164993 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT03164993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03164993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2017
Completion date
September 30, 2023
Enrollment
68 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, breast, triple negative breast cancer